Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Leist

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 21, 2017
The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS studyMark S Freedman, Thomas P Leist, Giancarlo Comi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
The Lancet. Neurology|February 8, 2014
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trialThomas P Leist, Giancarlo Comi, Bruce A C Cree, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 1998
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patientsT F Greten, J E Slansky, R Kubota, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 29, 2015
Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β TherapyJavad Rasouli, Bogoljub Ciric, Jaime Imitola, et al.
The Journal of Infectious Diseases|August 7, 1999
HTLV-I/II seroindeterminate Western blot reactivity in a cohort of patients with neurological diseaseS S Soldan, M D Graf, A Waziri, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 15, 2021
Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS studyMark S Freedman, Patricia K Coyle, Giancarlo Comi, et al.
Multiple Sclerosis and Related Disorders|February 10, 2016
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensionsGiancarlo Comi, Mark S Freedman, Ludwig Kappos, et al.
Multiple Sclerosis and Related Disorders|February 12, 2021
Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS studyBruce A C Cree, James D Bowen, Hans-Peter Hartung, et al.
Heliyon|August 11, 2021
N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosisShiva Shahrampour, Justin Heholt, Andrew Wang, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 21, 2017
The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS studyMark S Freedman, Thomas P Leist, Giancarlo Comi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 12, 2021
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock-Guttman, Robert Bermel, Gary Cutter, et al.
The Lancet. Neurology|February 8, 2014
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trialThomas P Leist, Giancarlo Comi, Bruce A C Cree, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 24, 1998
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patientsT F Greten, J E Slansky, R Kubota, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 29, 2015
Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β TherapyJavad Rasouli, Bogoljub Ciric, Jaime Imitola, et al.
The Journal of Infectious Diseases|August 7, 1999
HTLV-I/II seroindeterminate Western blot reactivity in a cohort of patients with neurological diseaseS S Soldan, M D Graf, A Waziri, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 15, 2021
Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS studyMark S Freedman, Patricia K Coyle, Giancarlo Comi, et al.
Multiple Sclerosis and Related Disorders|February 10, 2016
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensionsGiancarlo Comi, Mark S Freedman, Ludwig Kappos, et al.
Multiple Sclerosis and Related Disorders|February 12, 2021
Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS studyBruce A C Cree, James D Bowen, Hans-Peter Hartung, et al.
Heliyon|August 11, 2021
N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosisShiva Shahrampour, Justin Heholt, Andrew Wang, et al.
Pageof 8